Switching to tenofovir alafenamide in hbv: nationwide real life data of efficacy and safety from Turkey
Yıldız, İlknur Esen
Koç, Meliha Merih
MetadataShow full item record
CitationTabak, F., Yörük, G., Köksal, İ., Erdem, H., Yıldız, D., İnce, N.,...Güner, R. (n.d.). Switching to tenofovir alafenamide in hbv: nationwide real life data of efficacy and safety from Turkey. https://www.webofscience.com/wos/woscc/full-record/WOS:000707188002220
Tenofovir alafenamide (TAF) is a new prodrug of tenofovir used for the treatment of HIV-1 and HBV infections. It provides more efficient intracellular tenofovir concentrations at a relatively lower dose than provided by tenofovir disoproxil fumarate (TDF). TAF is expected to have efficacy similar to that of TDF with improved safety profile.